Trenonacog alfa

Drug Profile

Trenonacog alfa

Alternative Names: IB-1001; IXinity; Nonacog-alfa biosimilar - Emergent BioSolutions; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - Emergent BioSolutions; Recombinant factor IX biosimilar - Inspiration

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Inspiration Biopharmaceuticals
  • Developer Aptevo Therapeutics; Cangene Corporation
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 22 Aug 2016 CanGene withdraws a phase III trial for Haemophilia B (in adolescents, in adults) in the USA and the United Kingdom prior to enrolment (NCT02048111)
  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
  • 06 Aug 2015 Launched for prophylaxis and treatment of Haemophilia B (In Adults, In children) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top